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Abstract
Modern medicine has yet to produce selective treatments for the vast majority of cancer
types. Most chemotherapies, though complex, remain non-specific, and thus destroy healthy
cells. Over 25% of cancer patients die from the effects of chemotherapy before the actual tumor
would have progressed to the point of organismal death (Megget 2008). Early detection remains
the most accurate indicator of successful treatment outcome. But why wait until the disease
presents to deal with it? Here the authors argue that a well supported immune system coupled
with a dietary regimen of key food-based medicines is a far superior strategy. Given that many of
the successful drugs available today are naturally occurring, or designed from natural sources,
the authors suggest to look no further than the garden for biological wellbeing. The work
presented here aims to highlight a few of the relevant herbs and plants which can provide a
nutrient shield. Cancer is complex therefore our strategy must be equally complex.
In 2011, scientists Douglas Hanahan and Robert Weinberg consolidated our
understanding of cancer progression into ten “hallmarks of cancer”. The ten hallmarks of cancer
describe the ten steps required for a healthy cell to become tumorigenic. The ten hallmarks are:
sustaining proliferative signaling, evading growth suppressors, activating invasion and
metastasis, enabling replicative immortality, inducing angiogenesis, resisting cell death, avoiding
immune destruction, tumor promoting inflammation, genome instability and mutation, and
deregulating cellular energetics. It is in these ten areas that cancer must be addressed to properly
treat and prevent the disease from occurring. Cancer is a complicated disease. Unfortunately, the
one-drug for one-disease model is simply insufficient and outdated.
Though these hallmarks were identified several years ago, our understanding of them is
still in its early stages. The study of cancer over the last one hundred years has revealed the

staggering complexity of the cell. Within each human are trillions of cells, each with tens of
thousands of genes and hundreds of thousands of proteins, each working in unison to maintain
the health of the body. At its core, cancer is a hijacking of the cell’s remarkable complexity, and
therefore, the methods of prevention and treatment must match the complexity of disease.
Herein, the authors argue that the ten hallmarks of cancer provide a critical list of targets which
must be addressed. Further, the authors argue that natural sources of prevention (e.g. plants)
against these hallmarks are preferable, efficacious, and accessible.

Introduction

“The Saint treats those ill-to-be rather than those being ill, and cares for those in
normality rather than those in chaos. To drug a disease after it’s developed, or quench a chaos
after it’s evident is the same as digging a well when in thirst, or casting a sword in a battle —
Isn’t that somewhat too late?” – Emperor Shennong, 2800 B.C, Ancient China
Though modern medicine approaches cancer with novel technology, research, and
methods, the standard treatment strategy of surgery, radiation, and chemotherapy are antiquated.
The medical community has made groundbreaking advances in our understanding of the
complexity of tumorigenesis; however, treatment strategies have been slow to adjust
accordingly. The primary method of treatment remains attacking a single tumor characteristic at
a time, and that, only after tumor detection.
The uniqueness of cancer lies in its nature as an intrinsic disease. As opposed to an
infection by a foreign substance that the immune system can recognize as non-self, cancer results

when one’s own cells go rogue. Like an autoimmune illness, most cancers are a malfunctioning
of normal processes in the body. In The Biology of Cancer, Robert Weinberg describes cancer as
a “disease of chaos, a breakdown of existing biological order within the body” (Weinberg 2014).
Thus, cancer must be treated by restoring and supporting holistic order to the body. In 2011,
Douglas Hanahan and Robert Weinberg identified ten pathways that cancer hijacks within the
body’s natural biological order. The ten pathways were coined “Hallmarks of Cancer”. The
hallmarks outline the events required for tumorigenesis. By focusing on the key events required
for tumorigenesis, Hanahan and Weinberg, albeit inadvertently, have highlighted a thorough list
of where preventative measures should be focused. The hallmarks include sustaining
proliferative signaling, evading growth suppressors, activating invasion and metastasis, enabling
replicative immortality, inducing angiogenesis, resisting cell death, avoiding immune
destruction, tumor promoting inflammation, genome instability and mutation, and deregulating
cellular energetics. Each hallmark will in turn be discussed in detail, followed by the current
therapies targeting that tumor characteristic. Once a description of each hallmark has been given,
the authors will then identify naturally occurring, food-based plant products which can be used
as a prophylactic. Prophylactic, the word, comes from the Greek meaning, “an advance guard”.
The intent of the authors is to provide the general public with examples of plants which can
provide an advance guard against cancer progression. Though each hallmark represents a distinct
means by which cancer can arise in the body, the ten hallmarks are intertwined. It is when these
hallmarks merge that the complex disease state of cancer arises. Therefore, an effective approach
to cancer treatment requires a consideration of all ten hallmark characteristics at once.
Unfortunately, modern cancer therapy approaches treatment with an oversimplified view.
Although oncologists are aware that cancer is multifaceted, most therapies are focused on
treating just one hallmark at a time (O'Neill et al. 2018). As a result, standard treatment

procedures yield low efficacy due to their toxicity to healthy tissues and yield a high prevalence
of tumor recurrence via other hallmark pathways (Mokhtari et al. 2017). For example, ERPositive breast cancer is treated with a hormone blocker such as Tamoxifen, which targets only
one hallmark, sustaining proliferative signaling (American Cancer Society 2021 Oct 8). These
drugs generally yield low efficacy against non-ER positive cancer cells and can be incredibly
cytotoxic to healthy cells (Hassan et al. 2018). Tumors have been shown to upregulate alternative
pathways once a chemotherapy targets and deactivates the main pathway, e.g., sustaining
proliferative signaling, in an effort to maintain tumorigenesis (Hanahan and Weinberg 2011).
While hormone blocking drugs may very well prevent sustainment of proliferative signaling, the
tumor may work its way around that pathway and continue its pathogenesis via other hallmarks
(Hanahan and Weinberg 2011).
The result of such single-faceted cancer treatments is nearly 600,000 deaths from cancer
each year in the U.S. alone (CDC Division of Cancer Prevention and Control 2021). The authors
here argue that poor cancer outcomes are not only due to an oversimplified treatment standard,
but also occur because the disease of cancer is not addressed until it manifests. Although last
year in the US alone, nearly two million people were diagnosed with cancer, preventative
measures are yet to be integrated into standard medical treatment and care (CDC Division of
Cancer Prevention and Control 2021). Whether due to profitability, access, or a simple failure to
deviate from the medical norm, there are very few publicly accessible cancer prevention
strategies backed by peer-reviewed scientific support. Therefore, it is proposed that a focus be
given to cancer prevention and not just treatment. To accomplish this, the public must be
educated on the available resources and preventative measures at their disposal.
Early detection is a very strong predictor of successful cancer outcomes (World Health
Organization 2017). Consequently, the authors propose that cancer outcomes would be more

successful if the public was educated on ways to support the body’s tumor suppressive qualities
before a tumor manifests. Cancer is a multidimensional and dynamic disease that is difficult to
anticipate. A serious prevention strategy must address the multifaceted nature of the disease. To
date, there are only a few approved chemotherapies that can also be used as a cancer prophylaxis
(Cancer.Net Editorial Board 2019). Tamoxifen can be given to patients with a high risk of
developing ER positive breast cancer, and general Non-Steroidal Anti-Inflammatory Drugs
(NSAIDs) can lower the risk of a patient developing general cancer phenotypes (Cancer.Net
Editorial Board 2019). With both drugs, extreme or even deadly side effects are common in the
case of prolonged use, and each comes with the risk of being ineffective, as only one cancer
hallmark is being managed.
Cancer prevention can become accessible, safe, and effective, however, many of the Food
and Drug Administration (FDA) approved drugs are not doing the job. An advanced cancer
treatment strategy ought to begin with a robust and comprehensive prevention plan. To date, the
focus has centered on treatment once a tumor has developed. Many currently prescribed drugs
and chemotherapies are killing cancer cells only slightly faster than they are killing healthy
tissues. The result is a weakened immune system and a whole host of associated health issues.
The authors therefore propose that by enhancing our focus on prevention, and using our
deep understanding of how the body works with respect to the hallmarks of cancer, we can use
the steps of successful tumorigenesis as a guide for how we can best block this process from
every angle. The benefits of this approach would not only include fewer cancer cases, but also a
dramatic increase in overall health. By balancing cellular metabolism, excellent immune system
communication, supported DNA repair pathways, and decreased free radical damage, among
other health outcomes, quality of life will be enhanced while cancer progression is thwarted. The
good news is that help is growing just outside.

The majority of the cancer drugs on the market are chemically altered versions of
naturally occurring compounds found in plants and herbs. Medicinal compounds discovered by
pharmaceutical companies can be synthesized with slight changes to the chemical structure so
that they can be patented for monetization. While the authors appreciate the need to turn a profit,
many synthesized drugs come with contraindications that the natural version are free from. True
natural product could provide comparable efficacy without the contraindications that can result
from a chemically altered product (Winslow and Kroll 1998). In addition, the dietary supplement
industry is less regulated by the FDA than the pharmaceutical industry, often resulting in poorly
supported claims. Lack of supplement oversight by the FDA can also result in the presence of
understudied additives such as emulsifiers, preservatives, binders, and fillers, which can be found
on the shelves in prominent health food stores (Winslow and Kroll 1998). Consequently, many
of the herbal supplements available to the public are either poorly bioavailable, have lost their
true nutrient profile due to processing, or lack the medicinal compound they claim to contain,
rendering their benefits negligible (Bailey 2020). Though there are herbs and plants with welldocumented cancer preventative qualities, finding a consumable, accessible product that is
present in its purest, most bioavailable form can be difficult.
As such, the authors propose a ten-hallmark shield against the vulnerable biochemical
pathways of human cells. Using whole plants and herbs well established as therapeutics and/or
cancer preventatives, a natural, non-invasive, and over-the-counter, cancer prevention strategy is
proposed.

Hallmark

Current
Chemotherapy

Plant Alternative

Active Ingredient in Plant

Sustaining proliferative
signaling

EGFR and mTOR
inhibitors

Turmeric/ Kamala
Fruit

Curcumin/Rotterlin

Evading growth
suppressors

MDM
inhibitors/DNA
damage inducing
drugs

Berberis Plants/
Green Tea

Berberine/ Epigallocatechin
gallate (EGCG)

Activating invasion and
metastasis

Metalloproteinase
Inhibitors/c-MET
inhibitors

Black Chokeberries/
Antrodia cinnamonea
(fungus)

Caffeic Acid/ Antrocin

Enabling replicative
immortality

CDK
inhibitors/Telomerase
Inhibitors

Cruciferous
Vegetables/ Ginger

Indole-3-Carbinol/ Gingerol

Inducing angiogenesis

VEGF(R) inhibitors

Chinese Skullcap/
Chinese Wormwood

Baicalin/ Artemisinin

Resisting cell death

Pro-apoptotics

Graviola
Fruit/Garlic/Turmeric

– / Allicin 1/ Curcumin

Avoiding immune
destruction

Immunostimulants

Calendula/ Turkey
Tail Mushroom

Lutein/ Polysaccharide K
and P

Tumor promoting
inflammation

Aerobic Glycolysis
Inhibitors

Green Tea/ Olives

EGCG/ Oleanolic Acid

Genome instability and
mutation

Non-Steroidal AntiInflammatory Drugs
(NSAIDs)

Chinese Skullcap/
Turmeric

Baicalin/ Curcumin

Deregulating cellular
energetics

PARP inhibitors

Grapes/ Turmeric/
Green Tea

Resveratrol/ Curcumin/
EGCG

Table 1. Summary of Hallmarks of Cancer, current chemotherapies, and plant alternatives with
active ingredients. Lists are for reference and are not exhaustive.

Hallmark 1: Sustaining Proliferative
Signaling

The formation of abnormal and uncontrolled tissue growth, called a neoplasia, requires a
consistent input of growth signals to sustain its proliferation. Non-tumorigenic cells have tightly
regulated and specific growth signaling. Deregulation of these strictly controlled pathways is
present in almost all forms of cancer. Consequently, the pathways controlling cell growth and
division are often rife with proto-oncogenes, or genes that when mutated, carry a large likelihood
of inducing cancer ("PI3K / Akt Signaling" 2016). As such, when the genes that tightly control
growth and division are mutated, cancer phenotypes often follow. The main biochemical
pathways associated with proliferation require protein kinases. Protein kinases can activate
signaling cascades that will lead to increased transcription of growth factors.

Of particular interest are the phosphoinositide 3-kinase (PI3K) and serine/threonine (Akt)
kinase pathways, which play major roles in proliferative signaling. When bound by growth
ligands called epidermal growth factors (EGFs), cell surface receptors called epidermal growth
factor receptors (EGFRs) will activate the PI3K/Akt kinase pathway. The PI3K/Akt kinase
pathway has implications in the regulation of energy (ATP) production, angiogenesis (formation
of new blood vessels), nutrient management, cell repair, and cell survival (Yi et al. 2020).
Upregulated PI3K/Akt activity increases the expression of the mechanistic target of rapamycin
(mTOR), which controls nutrient and energy availability, as well as suppression of apoptotic
(programmed cell death) signaling. If overexpressed, the PI3K/Akt pathway allows for
uncontrolled growth signaling and suppression of apoptosis. The ability of the cell to avoid
apoptosis and trigger angiogenesis is essential for tumorigenesis and will additionally be
addressed in the hallmarks Resisting Cell Death and Inducing Angiogenesis.
Currently, standard chemotherapies for this hallmark focus on the suppression of mTOR
pathways, Epidermal Growth Factor Receptor (EGFR)/tyrosine kinase (TKIs), and the estrogen
receptor, which binds the hormone estrogen and has implications in cell growth and energy use.
Erlotinib, Gefitinib, Lapatinib, Cetuximab, Sirolimus, and Metformin are FDA approved
chemotherapies suppressing proliferative signaling via EGFR or mTOR inhibition. Most tumors
can quickly become resistant to their inhibitory effects (Chakraborty et al. 2021). In addition to
limited efficacy, side effects such as severe inflammation of the hair follicles (folliculitis), hair
loss (alopecia), iron deficiency (anemia), and severe swelling (edema) are common during the
course of therapy (Hartmann et al. 2009).
Here, the authors suggest the use of natural compounds with both mTOR and EGFR
inhibitory activity. Curcumin, a ketone in turmeric root, is the best documented of natural

compounds to have mTOR and EGFR inhibition properties (Stohs et al. 2020). Resveratrol, an
antioxidant found primarily found in the skin of grapes, rottlerin, found in the fruit of the kamala
tree, genistein, found in soy and fava beans, and quercetin, a flavonoid found in its highest
concentration in dill leaves, have all been shown to inhibit tyrosine kinases (Feitelson et al. 2015;
Dabeek and Marra 2019). The authors of this work suggest that curcumin, resveratrol, genestien,
and quercetin provide a non-toxic, accessible, and effective method of mitigating the sustainment
of proliferative signaling.

Hallmark 2: Evading Growth Suppressors

Evading growth suppression is an integral part of sustaining proliferation and is
considered a hallmark itself (Hanahan and Weinberg 2011). A tumor must both upregulate progrowth signals and become insensitive to growth suppressive cues from the environment.
Evading growth suppression and sustaining proliferation mark the early stages of tumorigenesis.
Each neoplasia must circumvent the tightly controlled growth mechanisms established in a cell.
In healthy cells, growth suppressors are the molecules that halt the signal for division and
replication until the checkpoints that scan for DNA integrity are completed successfully. If subpar environmental conditions or DNA damage is detected, growth suppressor molecules can
arrest the cell in its growth cycle until genome repair is completed or environmental conditions
are improved. Growth suppressor molecules have been dubbed the “guardians of the genome”

for their ability to protect both the cell and the organism from the accumulation of DNA
mutations and aberrant growth (Lane 1992).
Retinoblastoma protein (Rb) and protein 53 (P53) top the list of key growth suppressors.
Rb is a tumor suppressor that detects external environmental conditions and helps transduce
those signals into the cell (Hanahan and Weinberg 2011). The Rb protein affects many cellular
growth processes including replication control, cell senescence (cell aging), cell differentiation,
and cell apoptosis via signal transduction (Nahta et al. 2015). On the other hand, P53 receives
intracellular stress and genomic signals and determines the cell’s readiness for replication and
division. Because of their integral role in regulating cell cycle division, any defect or mutation to
Rb or P53 will likely result in aberrant growth (Lane 1992; Nahta et al. 2015).
Mutation is not the only method by which Rb or P53 activity can be dampened.
Hyperphosphorylation, or the unregulated addition of phosphate groups, to Rb results in its
degradation (Weinberg 1995). Rb hyperphosphorylation also can promote the premature
progression of the cell cycle from G1 to S, meaning that the cell will replicate its genome before
the proper safety checks have been completed (Nahta et al. 2015). P53 activity can be suppressed
via the upregulation of the Murine Double Minute (MDM) gene product, which codes for a
ubiquitin ligase (Tisato et al. 2017). Ubiquitin ligases are proteins that degrade other proteins.
The MDM oncoprotein can bind to P53, inhibiting P53’s tumor suppressive function via
degradation. Overexpression of the MDM protein occurs via gene amplification and results in
repression of P53 (Mendoza et al. 2014; Tisato et al. 2017).
The evasion of growth suppressors is currently addressed primarily through MDM
inhibitors in combination with DNA damage-inducing drugs such as cisplatin and doxorubicin.
Cisplatin and doxorubicin attempt to damage the genome enough to activate apoptosis via P53

(Dasari and Tchounwou 2014). One class of FDA approved MDM inhibitors adapted from the
nutlin molecule family has been shown to have great efficacy in preventing the suppression of
P53 (Candido et al. 2019). Though the nutlin molecule MDM inhibitor is effective, it also causes
severe hemotoxicity, or toxicity to red blood cells. Over-inhibition of MDM proteins results in
the disruption of red blood cell formation (hematopoiesis). As a result, these drugs often come
with severe gastrointestinal malaise (Tisato et al. 2017). Overall, MDM inhibitors are being
investigated to improve their low efficacy, poor bioavailability, and toxic side effects (Arnhold et
al. 2018). DNA damage inducing drugs are a last resort chemotherapy due to the damage caused
to healthy tissues. Given to tumors where cells are dividing rapidly without inhibition or
regulation, doxorubicin is an alkylating agent that introduces double-stranded breaks into the
genome with the hopes of activating P53 to arrest the cell cycle and stop growth (Weber 2015).
The authors of this paper argue that inducing DNA damage is not the most effective
approach for evading growth suppressors. Rather, proper support of both P53 and Rb function is
recommended via plant-based medicines which could provide effective and nontoxic results.
Several natural compounds have been shown to inhibit MDM and promote P53 activity and
longevity. Natural MDM inhibitors include compounds such as berberine, curcumin, genistein,
and apigenin (Qin et al. 2012). Berberine, an alkaloid found primarily in the Berberis genus, a
shrub family grown in subtropical regions, has been shown to both downregulate MDM protein
activity as well as enhance P53 activity (Neag et al. 2018). The authors suggest the following
P53 activators and enhancers: Epigallocatechin Gallate (EGCG), luteolin, lutein, resveratrol, and
glycyrrhizic acid. EGCG is the major polyphenol found in the leaves of green tea. EGCG
supports P53 expression and activity, as well as proper cell cycle function. EGCG has thus been
widely considered a key part of herbal cancer prevention (Du et al. 2012). Luteolin and lutein are

flavonoids that have been shown to increase P53 activation (Amin et al. 2015; Cruceriu et al.
2018). Luteolin is found in a variety of plants and herbs, the most notable being Mexican
oregano, Chinese celery, and Queen Anne’s Lace (Bhagwat et al. 2016). Lutein is found
primarily in the herb Calendula, commonly known as pot marigold, and participates actively in
supporting cell cycle arrest (Cruceriu et al. 2018). Resveratrol, as seen in sustaining proliferative
signaling, is also noted for its P53 activating effects. In addition, glycyrrhizic acid, found
primarily in licorice root, has been noted not only for its ability to mitigate the off-target effects
of cisplatin cancer treatments, but for its ability to promote P53 activity (Amin et al. 2015).
Lastly, EGCG and 1,25-dihydroxivitamin D (Vitamin D) have been found to reduce Rb
hyperphosphorylation, thus enhancing Rb’s longevity. Stabilizing Rb allows it to better control
cell cycle arrest and manage overgrowth and over-proliferation. The authors suggest further
study and use of green tea, Mexican oregano, licorice root, and Berberis plants for their nontoxic cancer preventative qualities in the Evading Growth Suppression hallmark.

Hallmark 3: Activating Invasion and
Metastasis

Hanahan and Weinberg have identified the third hallmark as the distinguishing factor
between benign and malignant tumors. A benign tumor is one that has not outgrown its tissue of
origin or invaded adjacent tissues (Weinberg 2014). On the contrary, malignancy is a term used
to describe aberrant growths which have expanded into adjacent tissues or have generated “new
settlements” in the body, otherwise known as metastases (Weinberg 2014). Due to the
implications of this event, invasion and metastasis is a key feature of true tumorigenesis
(Meirson et al. 2020).
The protein E-cadherin is a key player in the activation of invasion and metastasis.
Functioning as the ‘lock and key’ to tissue stability, E-cadherin is a cell-to-cell adhesion

molecule that maintains epithelial tissue integrity and organization via adherens junctions
(Mohan et al. 2018). In healthy tissues, epithelial cells are highly organized and strictly
regulated. Mutations in or down-regulation of E-cadherin is a fundamental step enabling tumor
malignancy and metastasis. E-cadherin instability allows for the dissociation of a tumor from its
tissue of origin and subsequent travel to new tissue locations (Gandalovičová et al. 2017). Tumor
metastasis is achieved through a process known as the epithelial to mesenchymal transition
(EMT) (Zhitnyak et al. 2020). EMT is the process in which a stable epithelial cell undergoes
changes that result in the cell taking on the characteristics of a migratory mesenchymal cell.
Migratory epithelial cells tend to have a heightened ability to invade foreign tissues, avoid
apoptosis, and degrade the extracellular matrix (ECM), all of which increase the severity of the
cancer (Kalluri and Weinberg 2009). The EMT is a normal biochemical process that exists for
wound healing and during organismal development; however, when EMT occurs outside of the
properly regulated time and place, it enables tumorigenesis (Kalluri and Weinberg 2009). The
EMT process is also capable of operating in reverse. When a mesenchymal cell becomes
epithelial, this is called a mesenchymal to epithelial transition (MET). MET’s can result in the
settlement of new metastases away from their tissue of origin to establish a tumor in a new
location (Hanahan and Weinberg 2011). The ability to switch back and forth between EMT and
MET allows for increased malignancy.
In addition to E-cadherin, the Hepatocyte Growth Factor (HGF)/c-Met signaling pathway
strongly promotes invasion and metastasis. c-MET is a receptor tyrosine kinase that binds HGF
to induce tissue motility and invasion (Organ and Tsao 2011). Upregulation of this pathway is
necessary for metastatic tumors to invade foreign tissue (Uchikawa et al. 2021). Hypoxia, or low

oxygen availability, is known to induce the HGF/c-Met pathway. Hypoxia is also a key factor in
hallmark deregulation of cellular energetics, which is discussed below.
To begin the process of invasion, metastatic tumors must acquire the ability to degrade
and modify the extracellular matrix (ECM) (Xu et al. 2009). The ECM is the meshwork of
supporting matter immediately surrounding the cell. Degradation of the ECM is a necessary
process that occurs in embryonic cells and in normal cells during wound healing and tissue
growth. Tumors, however, use ECM degradation to achieve malignancy by digesting the
physical barrier that the ECM poses to adjacent tissues. ECM breakdown is accomplished by
metalloproteinases, enzymes that digest the vast connective network of the ECM (Itoh and
Nagase 2002). Upregulation, or overproduction, of metalloproteinases is a characteristic of
migratory neoplasia and is a key target of metastasis-specific chemotherapies (Kalluri and
Weinberg 2009).
The activation of invasion and metastasis is currently treated with migrastatic drugs that
attempt to prevent or stop tumor movement. Migrastatics come in the form of metalloproteinase
inhibitors (MPI’s) and HGF/c-Met inhibitors. Many of these drugs must be taken consistently
over an extended period to be effective and can be incredibly cytotoxic to healthy cells
undergoing wound healing and repair (Gandalovičová et al. 2017). MPI’s are generally
successful in treating early-stage tumors and premetastatic lesions but tend to have negligible
effects after malignancy has been achieved (Winer et al. 2018). Though metalloproteinases were
initially seen as an ‘easy’ target for cancer therapy, most clinical trials of MPI’s have been
unsuccessful and yielded disappointing results (Coussens et al. 2002). HGF/c-Met inhibitors are
a class of tyrosine kinase inhibitors that reduce phosphorylation of the HGF/c-Met pathway,
reducing tumor scattering and motility (Demkova and Kucerova 2018). In clinical trials,

targeting the HGF/c-Met pathway has been shown to cause severe adverse side effects such as
neutropenia (low neutrophil count), anemia (low iron) increased susceptibility to tissue damage,
and hypertension (Hu et al. 2017).
Several natural compounds are known to have migrastatic capabilities through E-cadherin
upregulation and the downregulation of EMT pathways. The authors argue that supporting these
pathways instead of inhibiting metalloproteinases and the HGF/c-Met pathway is a more holistic,
less cytotoxic approach to preventing the activation of invasion and metastasis. Natural
migrastatics include caffeic acid, α-solanine, antrocin, sulforaphane, eugenol, ginsenoside and
honokiol. Caffeic acid (CA) is a polyphenol shown to increase the expression of E-cadherin in
genital and urinary cancers (Song et al. 2019). Caffeic acid is commonly known for its presence
in tea and coffee, however black chokeberries, Ceylon cinnamon, sage, and thyme have the most
abundant levels of CA (Neveu et al. 2010). α-Solanine is a glycoalkaloid found in vegetables
belonging to the nightshade family such as tomatoes, eggplants, and white potatoes (Song et al.
2019). Low doses of α-Solanine have been shown to decrease metastasis via the elevation of Ecadherin expression as well as the suppression of EMT pathways (Shen et al. 2014). α-Solanine
became of interest to naturopath clinicians for its proposed inflammatory effects on arthritic and
autoimmune patients, causing many naturopathic practitioners to instruct their patients to avoid
nightshade vegetables. To date there are no official studies documenting this effect or reasoning
for the observed symptoms, so moderate doses of α-Solanine can generally be regarded as safe
however usage should be decided on a patient-practitioner basis. Antrocin, a major component of
the fungus Antrodia cinnamonea, has been shown to suppress colonization of metastases in
foreign tissues (Chen et al. 2019). Ginsenoside, a steroid glycoside found in high concentrations
in panax ginseng, has been shown to have anti-EMT properties in ovarian cancer (Song et al.

2019). Sulforaphane is a sulfur-rich compound that has been noted for its strong anti-cancer
properties, especially in its anti-metastatic behavior via E-cadherin expression (Agbarya et al.
2014). Sulforaphane is most highly concentrated in broccoli sprouts, the beginning growths of
the broccoli plant (Tian et al. 2017). Finally, eugenol, otherwise known as clove oil, has been
shown to have dose and time-dependent inhibitory effects on metastasis in breast cancer lines
(Abdullah et al. 2018).

Hallmark 4: Enabling Replicative
Immortality

The fourth hallmark, enabling replicative immortality, is closely tied to the hallmarks
sustaining proliferative signaling and resisting cell death. A tumor’s ability to avoid cell
senescence (or cellular aging) is the defining characteristic of enabling replicative immortality. If
a cell begins to over proliferate, that cell can induce a non-proliferative state where the cell cycle
is arrested in G1. Rreplication and division is irreversibly halted even though the cell stays viable
(Hanahan and Weinberg 2011). This is called cell senescence and is different from cell
quiescence, the process in which a cell is arrested into G0 of the cell cycle and replication and
division are temporarily paused (Dulic 2013). Cells use senescence as a fail-safe mechanism by
inducing this non-proliferative state after a certain number of mitotic divisions. Consequently, if

a cell is dividing too rapidly or growing beyond its means, senescence is triggered to stop
aberrant growth and potential tumor formation. Senescence is also closely linked to telomere
length and cellular aging. Telomeres are the string of nucleic acids at the end of chromosomes.
After each cell division, a chromosome’s telomeres are shortened as replication causes the last
few nucleotides of the lagging strand to be lost on the daughter strand. Once the entire telomere
is lost, the chromosome can begin losing important genes, linking telomere length to cellular
aging (senescence) and loss-of-function in the organism. In theory, each cell has a pre-set
number of programed divisions allowed before the cell becomes senescent due to chromosomal
shortening. Many neoplasias are stopped during their growth due to the triggering of either cell
senescence or apoptosis. Cells with the ability to circumvent senescence are highly prone to
producing malignant tumors (Hanahan and Weinberg 2011).
Telomerase is the enzyme that repairs chromosomal telomeres. Telomerase is encoded by
the gene hTERT and is usually epigenetically silenced (turned off) in most normal somatic cells
(Jafri et al. 2016). Cancer cells must express and upregulate hTERT to allow for telomere repair
after each division, preventing chromosomal shortening. Upregulation of telomerase allows for a
far greater number of cell cycles than is possible with normal telomerase expression patterns
(Jafri et al. 2016). As a result of upregulated telomerase expression, cellular senescence is
avoided, and replicative immortality is possible.
The cell cycle progresses via cyclins and cyclin dependent kinases (CDKs). Known as
cell cycle checkpoint molecules, CDKs are responsible for phosphorylating cyclins. Cyclins
cannot push the cell cycle forward until they are phosphorylated. Increased levels of CDKs lead
to greater cyclin phosphorylation, which in turn results in increased progression through the cell
cycle. Cancer cells are known to upregulate expression of CDKs to push the cell cycle forward,

contributing to replicative immortality. Additionally, P53, the “guardian of the genome”,
regulates the cell cycle by regulating the phosphorylation of cyclins by CDKs when the cell is
not ready for replication and can pause progression or even trigger apoptosis when necessary.
Cancer cells upregulate CDK’s to fuel growth progression while dampening the activity of P53
(Lin et al. 2018).
Triggering cell senescence has become a key target in chemotherapy development
(Hanahan and Weinberg 2011). Unfortunately, cell senescence is a very difficult hallmark
feature to induce, as the induction of senescence is achieved via many intertwined biochemical
pathways (Yaswen et al. 2015). The current chemotherapies being used to target replicative
immortality include CDK inhibitors and telomerase inhibitors. To date, most CDK inhibitors
have not received FDA approval. Only a few, such a palbociclib and dinaciclib, have been
approved due to their relatively low toxicity and efficacy (Law et al. 2015). CDK1 is the only
protein of its class essential for normal cell cycle progression and is typically not the molecule
being expressed in cancer cells. As such, CDK inhibitors that target CDK4 or CDK6 are
generally the most effective and least cytotoxic to healthy cells (Zhang et al. 2021).
Nevertheless, the exact mechanisms by which CDK inhibitors suppress tumors are still unclear.
Side effects for FDA approved CDK inhibitors include gastrointestinal disturbances, neutropenia
(low neutrophil count), leukopenia (low white blood cell count), and anemia (low iron levels)
(Law et al. 2015). Telomerase inhibitors are short pieces of DNA designed to induce apoptosis or
senescence and are typically administered via vaccination (Jafri et al. 2016). Currently, imetelstat
is the only FDA approved telomerase inhibitor. Imetelstat works as a competitive inhibitor,
binding the RNA primer used by telomerase to bind the telomere (Baerlocher et al. 2015).
Imetelstat side effects include thrombocytopenia (low blood platelet count), gastrointestinal

disturbances, and infusion reactions (Baerlocher et al. 2015). Additionally, genotoxic drugs,
drugs that can induce chromosomal damage, can trigger either senescence or apoptosis, targeting
replicative immortality (Yaswen et al. 2015).
Several natural compounds have been identified which have telomerase inhibitory
activity and the ability to induce cell cycle arrest. These compounds work to induce cellular
senescence and inhibit replicative immortality. Telomerase inhibition can come in the form of
direct competition and/or reduction of hTERT expression. Indole, diosgenin, and gingerol have
been attributed with anti-telomerase activities. Indole-3-carbinol (I3C) is a compound that results
from the body’s breakdown of glucosinolates found in cruciferous vegetables such as broccoli,
kale, and brussels sprouts (Katz et al. 2018). I3C inhibits telomerase by downregulating hTERT
expression and has also been shown to induce cell cycle arrest at G2 (Ganesan and Xu 2017).
Furthermore, cruciferous vegetables are high in sulforaphane, as mentioned in activating
invasion and metastasis, adding to their already potent anticancer effects (Agbarya et al. 2014).
Diosgenin, a product of sapogenin hydrolysis in wild tuber vegetables, has been shown to
downregulate hTERT expression (Ganesan and Xu 2017). Gingerol, the main bioactive
polyphenol in ginger root, contributes to telomerase inhibition while also providing an overall
anti-inflammatory effect. Given the dual efficacy of gingerol, daily intake is likely to be key for
cancer prevention (Kaewtunjai et al. 2018). Additionally, resveratrol, genistein, epigallocatechin,
berberine, and curcumin have all been shown to antagonize replicative immortality via hTERT
downregulation (Kaewtunjai et al. 2018).
One Traditional Chinese Medicine (TCM) blend has been used for centuries for its antitumor benefits. Yangyinjeidu (YYJD) is a blend of Astralagus propinquus (astralagus), Radix
ophiopogonis (Ophiopogon root), Paris polyphylla (Paris herb), Ligustrum lucidum (glossy

privet fruit), and Gynostemma pentaphyllum (fiveleaf ginseng). YYJD has recently been studied
for its effects on cancer cells. YYJD has been shown to induce cell cycle arrest before mitosis
and induce cell senescence (Zheng et al. 2017).

Hallmark 5: Inducing Angiogenesis

Angiogenesis is the process in which new blood vessels are formed from preexisting
ones, allowing tissues access to oxygen, nutrients, and water. Angiogenesis is active in an
organism primarily during fetal development, after which it is diminished and is tightly regulated
until needed for wound healing or at certain points in the female pregnancy-lactation cycle
(Hanahan and Weinberg 2011). If angiogenesis is activated outside of the normal instances listed
above, tumor growth, over-proliferation, and tissue invasion are likely, making angiogenesis a
key part of tumorigenesis and sustained malignancy. The “angiogenic switch” is a term given to
the point at which the pro-angiogenic factors overtake the anti-angiogenic factors, allowing for
the formation of new blood vessels that sustain neoplastic growth (Baeriswyl and Christofori
2009). Vascular Endothelial Growth Factor (VEGF) protein plays a key role in regulation of
blood vessel growth and supply of nutrients and oxygen to tissues. Upregulation of VEGF and its

receptor, VEGFR, accomplished by hypoxia, inflammation, or oncogene signaling, is common to
most forms of malignant cancers (Hanahan and Weinberg 2011). Fibroblast Growth Factor
(FGF) is also a common pro-angiogenic factor whose chronic upregulation is found in malignant
tumors (Agbarya et al. 2014).
Common angiogenesis inhibitors include Axitinib, Pazopanib, Vandetanib
("Angiogenesis Inhibitors - National Cancer Institute" 2018). These drugs are used both alone
and in neoadjuvant therapy (chemotherapy given before surgical tumor removal) to increase the
efficacy of curative surgery (Vasudev and Reynolds 2014). Angiogenesis inhibitors can either
target VEGF or its receptor, VEGFR. Angiogenesis inhibitors are often ineffective against
breast, prostate, and ovarian cancers as these tumors can quickly develop drug resistance
(Gaitskell et al. 2011). In addition to their inefficacy against certain cancers, angiogenesis
inhibitors targeting VEGF can cause hemorrhaging, blood clotting, resultant heart attacks,
impaired wound healing, hypertension, and in rare cases brain disorders. Angiogenesis inhibitors
targeting VEGFRs can induce fatigue, hypothyroidism, and cardiac failure ("Angiogenesis
Inhibitors - National Cancer Institute" 2018).
Natural VEGF inhibitors have been identified in many plants including Chinese skullcap,
Chinese wormwood, and turmeric. Baicalin, a compound extracted from Chinese skullcap, has
been used for its striking ability to reduce blood vessel cell proliferation via VEGF suppression
(Sagar et al. 2006). Furthermore, the activity of baicalin has been shown to be effective even in
advanced prostate cancer (Miocinovic et al. 2005). Artemisinin, a major terpene in Chinese
wormwood, has been shown to significantly reduce angiogenesis in vivo (Sagar et al. 2006).
Artesunate (ART), a synthetic derivative of artemisinin, is used for its anti-angiogenesis
properties via VEGF repression. ART has also been used to safely treat malaria and has promise

as an angiogenesis inhibitor (Chen et al. 2004). The authors argue that the non-synthetic
artemisinin is the preferred, superior form to use in the inhibition of angiogenesis. Retinol, or
retinoic acid, has also been shown to have anti-angiogenic qualities via down-regulation of
VEGF (Lu et al. 2011). Vitamin A is converted to retinoids in the body, which then exert their
anti-cancer effects. Though beef liver has the highest levels of vitamin A, there are also plants
and herbs with high retinoic acid activity, such as sweet potatoes, basil, paprika, and cayenne.
Additionally, curcumin and EGCG have anti-angiogenic properties (Sagar et al. 2006).

Hallmark 6: Resisting Cell Death

Apoptosis is the process in which a cell triggers its own death due to internal cell
conditions that have damaged the cell beyond repair. Proper apoptotic regulation is key to a
healthy organism, as triggering death in a few rouge cells does much less harm to a tissue than
the uncontrolled replication of damaged cells. Apoptosis is controlled by extrinsic and intrinsic
pathways. The extrinsic pathway is regulated by the molecule caspase 8 and the Fas ligand,
while the intrinsic pathway is directed by the molecule caspase 9 and the B-cell Lymphoma
(BCL) family of proteins (Sharma et al. 2019). The intrinsic BCL pathway has pro and antiapoptotic domains that must stay in a delicate balance for proper regulation. The intrinsic
caspase pathway is more closely associated with apoptosis, meaning mutations or regulatory
complications with this pathway are strongly associated with cancer.

Cancer cells are more susceptible to apoptosis than healthy cells due to their deregulated
signaling and metabolism, abnormal tumor microenvironment, and typical lack of nutrient
availability, all of which alert the cell that internal conditions are unfavorable to survival. In
order to thrive, cancer cells must find a way to circumvent apoptotic signaling and avoid cell
death (Sharma et al. 2019). One way of accomplishing this is by the downregulation of BH3 proapoptotic activators, and upregulation of Bcl-2 anti-apoptotic repressors. (Pfeffer and Singh
2018). P53 upregulates the expression of BH3, and can bind Bcl-2, stopping apoptotic inhibition
(Gerl and Vaux 2005). Downregulation of P53 will cause decreased expression of BH3 and
increased Bcl-2 activity, enabling an evasion of apoptosis (Sharma et al. 2019). Furthermore,
tumor cells have been studied for their ability to resist cell death via the formation of
blebbishields, a last-ditch resort for apoptotic cancer cells. Blebbishield are a collection of small,
membrane-enclosed spheres called blebs, which fuse and surround tumorigenic cells, shielding
them from the binding of apoptotic signals and allowing for tumor survival (Jinesh et al. 2013).
The induction of apoptosis is one of the most effective non-invasive treatment methods
due to its integral role in the removal of tumorigenic cells (Pfeffer and Singh 2018). As opposed
to being directly cytotoxic, pro-apoptotic drugs (drugs that induce cell death) aim to upregulate
the mechanisms by which cell death is naturally achieved. Pro-apoptotics are typically less
harmful to healthy cells than genotoxic drugs (Gerl and Vaux 2005). Bcl-2 antagonist drugs such
as Venetoclax act as a BH3 mimetic, reducing the suppression of apoptotic signaling via
repressors (Sharma et al. 2019). Oncologists are currently looking at the prospects of combining
pro-apoptotics and statins for a more-effective anti-cancer therapy, as the regulation of cellular
energetics and apoptosis are closely related (Hanahan and Weinberg 2011).

A variety of natural compounds have been discovered with Bcl-2 antagonist activity or
with the general ability to upregulate apoptotic activity. Graviola, a fruit native to tropical
regions, has been shown in vivo to have specific pro-apoptotic properties (Rady et al. 2018).
Because graviola has a large phytochemical profile (containing a large variety of vitamins,
flavanoids, alkaloids, phenols, and other micro-nutrients present in the fruit) the specific
secondary metabolites with anti-cancer activity have yet to be identified, however extracts of this
fruit have shown to antagonize Bcl-2 while upregulating BH3 without cytotoxicity to healthy
tissues (Pfeffer and Singh 2018). Genistein has anti-cancer effects on breast and prostate cancers
via the induction of apoptosis (Lewis and Elvin-Lewis 2003). Garlic and astralagus root have
been noted to contain pro-apoptotic qualities both in vivo and in vitro on cervical cancer (HeLa)
cells (Kooti et al. 2017). Bryonia aspera, a vine-like herb found in Himalayan regions, has
recently been shown to be very effective in inducing apoptosis in HeLa cancer cells. Further
studies of B. aspera’s cytotoxicity and mechanisms of action should be conducted (Pourgonabadi
et al. 2017). Eugenol, curcumin, quercetin, and lutein have all been demonstrated to have proapoptotic activity (Abdullah et al. 2018; Cruceriu et al. 2018; Pfeffer and Singh 2018).
Additionally, herbs and plants identified with the ability to support and upregulate P53
expression will support the prevention of this hallmark as well (see Hallmark 2). It is therefore
argued that the most effective treatment strategy against this hallmark is to support the cells’
inherent ability to trigger programed cell death via naturally occurring compounds.

Hallmark 7: Avoiding Immune Destruction

The human immune system functions by recognizing not only foreign organisms, but also
self-cells which have become infected or that have lost their ability to trigger apoptosis.
However, the job of the immune system to attack and destroy foreign invaders becomes
convoluted when the tissue antagonist is native to the organism. Cancer cells must develop the
ability to appear normal to the immune system, while undergoing aberrant growth, in order to
remain undetected by the immune system. When the immune system cannot recognize a cell as
infected or defective, that cell evades an immunogenic attack and can continue to proliferate
(Hanahan and Weinberg 2011). To make matters worse, cancer treatments such as radiation and
chemotherapies are specifically cytotoxic to immune cells. The result of many cancer treatment
strategies is a weakened immune system and an increased likelihood for evasion of cancer cells
from an immune response (Rébé and Ghiringhelli 2015).

Cancer cells have been noted with the ability to evade certain immune cells, especially
cytotoxic CD8 T cells. Evasion of CD8 cells is accomplished by the loss of the major
histocompatibility complex (MCH) which aids adaptive immune cells in the recognition of
foreign substances (Dhatchinamoorthy et al. 2021). Contrastingly, increased levels of other
immune cells, especially those part of the innate immune inflammatory response, have been
detected in tumors. The result is a dichotomy in the role that the immune system plays in cancer.
Many cancer researchers originally assumed that the increased levels of immune cells were
simply due to the immune system responding to abnormal tissue growth (Hanahan and Weinberg
2011). More recent studies have shown that the presence of innate immune cells around tumorrelated stroma is contributing to tumorigenesis as opposed to combating it (Grivennikov et al.
2010).
The cells of the innate immune system induce the inflammatory response. In a healthy
setting, inflammatory signals will recruit pro-growth molecules, pro-angiogenic factors, and antiapoptotic signals which allow for wound healing and tissue repair upon damage. However, in
cancerous tissue, the upregulation of inflammatory signals allows for recruitment of these
molecules to support growth, blood vessel growth, and cell survival of the tumor (Hanahan and
Weinberg 2011). While inflammation via innate immune cells enables tumor growth and
survival, cancer cells must also evade detection by the adaptive immune system to avoid
destruction. Tumor cells may work to suppress the adaptive immune response through the
secretion of immunosuppressive factors and by targeting t-cell function and antigen presentation
(Vinay et al. 2015).
Presently, suppression of the adaptive immune response and activation of the proinflammatory immune response are being treated with immunostimulants focused on T-cell and

dendritic cell activation, and anti-inflammatories, respectively. Four FDA approved therapies are
currently in use that promote adaptive immune cell maturation and activation. The FDA
approved therapies work by the four following mechanisms: increasing maturation of T-cells by
receptor activation; activating dendritic cells by extracting a patient’s mononuclear cells,
increasing immune recognition with prostatic acid phosphates, then reintroducing the cells back
into the patient’s body; neutralizing immunosuppressive molecules released by cancer cells with
substrate-specific antibodies; and inhibiting the PD-L1 ligand that binds and inactivates the PD-1
receptor on T-cells (Messerschmidt et al. 2016). T-cell overactivation and subsequent autoimmunities are a major side effect of these therapies. A better understanding of the role the
immune system plays in tumor progression will be necessary to improve the treatment and
prevention of avoiding immune destruction.
A simple, yet effective way of naturally increasing immune surveillance is through
lymphatic stimulation. When fluids are properly circulating in the body, the likelihood of
recognition is increased. With increased circulation comes an increase in the likelihood that
immune cells will detect and destroy cancer cells. Calendula, in addition to its other anti-cancer
benefits discussed earlier, contains the carotenoid lutein which is known to be an excellent
lymphatic stimulant (Cruceriu et al. 2018). Lymphatic circulation, however, does not solve the
ability of cancer cells to evade immune detection and destruction.
There is, however, a way to directly address the evasion of immune detection by cancer
cells. Medicinal mushrooms have been used since 3000 B.C.E. in the treatment of a variety of
ailments (Guggenheim et al. 2014). Certain medicinal mushrooms have unique polysaccharides
called β-glucans that activate the specific immune cells which attack tumors. Extracts of these
medicinal mushrooms have been successfully used for many years in Japan and China as an

adjuvant therapy following cancer diagnosis (Jeitler et al. 2020). Krestin (polysaccharide K) and
polysaccharide P are β-glucans found in Coriolus versicolor (turkey tail mushroom) that function
as biological response modifiers (BRMs) (Fisher and Yang 2002). BRMs show promise in
improving the host-versus-tumor response, and therefore, decrease a tumor's ability to evade the
immune response. The exact mechanism of β-glucans bolstering of the immune response has yet
to be elucidated. It is known, however, that medicinal mushroom extracts of Agaricus, maitake,
reishi, Cordyceps, and Coriolus can regulate the expression of tumor associated cytokines (cell
signaling molecules) to increase the immune response to cancer (Guggenheim et al. 2014).
Additionally, medicinal mushroom extracts have been shown to improve the immune system’s
identification of the cell surface recognition molecules expressed on cancer cells, known as the
major histocompatibility complex (MHC). Greater MHC recognition allows the immune system
to be better educated when recognizing and killing tumor cells attempting to evade destruction
(Patel and Goyal 2012). The authors therefore propose that a diet rich in medicinal mushrooms is
indispensable for maintaining healthy immune system function.
Additionally, many herbs have been noted with immunostimulant activity. Intravenous
deliveries of ginseng, astralagus, and echinacea are common supplementary treatments for
cancer patients throughout Europe, however, these treatments are not currently FDA approved in
the U.S. (Block and Mead 2003). Ginseng, astralagus, and echinacea have been shown to
increase general macrophage activity, stimulate antibody production, and upregulate interleukin
2 and tumor necrosis factors (TNF) (Block and Mead 2003).

Hallmark 8: Deregulating Cellular
Energetics

In 1930, Otto Warburg discovered the unique way that cancer cells process glucose in the
presence of oxygen. In normal, oxygen-rich conditions, glucose is converted to pyruvate and
then sent to the mitochondria, producing large amounts of energy (ATP). In anaerobic
conditions, glucose is converted to pyruvate, after which it is fermented into lactic acid,
producing only a fraction of the ATP that can be made in aerobic conditions. Warburg observed
cancer cells processing glucose through fermentation, though in normal aerobic conditions. This
phenomenon, called aerobic glycolysis, is done by triggering the “glycolic switch,” or the switch
of processing glucose in an anaerobic fashion, while in an aerobic environment. To sustain
proliferative signaling, cancer cells must both upregulate pro-growth signals (see Hallmark 1)

and alter their metabolism via the deregulation of cellular energetics (Hanahan and Weinberg
2011).
The use of glycolysis as a major source of energy production in cancer seems
counterintuitive due to its decreased ATP production. Glycolysis is contrastingly beneficial to
tumors, as the glycolic intermediates can be diverted from the ATP production pathway and
turned into amino acids and other important proliferative molecules that the tumor can use to
grow (Hanahan and Weinberg 2011). Cancer cells compensate for reduced ATP synthesis by
increasing glucose import into the cell via upregulation of Glucose transporter 1 (GLUT1), the
cell surface glucose transporter (Zambrano et al. 2019). Eventually, two groups of cancer cells
begin to coexist in a single tumor type. The first performs glycolysis from imported glucose,
creating lactate as a fermentation product. The second uses the lactate and converts it to ATP via
aerobic respiration. This process, called the “Warburg Effect,” allows for the energetically
different tumor cells to function symbiotically, and thus enhance tumorigenesis (Hanahan and
Weinberg 2011). The deregulation of cellular energetics is closely tied to many of the other
hallmarks, as aerobic glycolysis is an enabling characteristic of proliferative signaling,
metastasis, and angiogenesis.
The deregulation of cellular energetics is currently being treated with aerobic glycolysis
inhibitors that block certain glycolic intermediates such as phosphofructokinase, hexokinase, or
aldolase (Pelicano et al. 2006). Targeting these intermediates is generally safe as healthy cells do
not typically rely on glycolysis alone for energy. It is also possible to inhibit aerobic glycolysis
by blocking GLUT1, though this method is more toxic to healthy cells since GLUT1 is expressed
in all somatic cells (Ganapathy-Kanniappan and Geschwind 2013). Studies show that forcing

cancer cells to revert to oxidative phosphorylation results in cell death, revealing that targeting
this hallmark shows promise in anti-cancer therapy (Bonnet et al. 2007).
Only a few drugs targeting aerobic glycolysis are currently in clinical trials
(Xintataropoulou et al. 2015). The authors here argue that the following herbal treatments
warrant further investigation for prevention of the deregulation of cellular energetics. Berberine
and curcumin have been shown to inhibit aerobic glycolysis by disrupting the glycolic
intermediate hexokinase (Zhong et al. 2016). EGCG can inhibit lactate and therefore prevent the
Warburg Effect (Zhong et al. 2016). Oleanolic acid, the major terpenoid in olives and olive oil,
reduces aerobic glycolysis-related proliferation, as well as interrupts essential biochemical
pathways of the hallmarks influenced by hypoxia as stated above (Li et al. 2019).

Hallmark 9: Tumor Promoting
Inflammation- an Enabling Characteristic

The previous eight hallmarks are characteristics that allow a tumor to grow, survive, and
invade. The final two hallmarks, tumor promoting inflammation and genome instability and
mutation, were identified as enabling characteristics that allow a tumor’s acquisition of the other
eight hallmark capabilities (Hanahan and Weinberg 2011). The hallmark tumor promoting
inflammation is linked to the hallmark avoiding immune destruction. As briefly mentioned
above, a tumor must simultaneously evade the adaptive immune response and increase the innate
immune inflammatory response. Inflammation is a beneficial immediate response to abnormal
invaders or tissue damage, but sustained inflammation is a driver of several disease states. The

damage a neoplasia does to adjacent tissue typically signals the inflammatory response that is
sustained as the growing mass remains and is not eliminated.
Chronic inflammation enhances tumorigenesis by providing the tumor microenvironment
with growth factors and other signals that enable tumor progression. Specifically, inflammation
promotes metastasis through EMT upregulation, angiogenesis by tumor-associated macrophage
(TAM) recruitment, and proliferation by activation of inflammatory cytokines (Grivennikov et
al. 2010; Hanahan and Weinberg 2011). TAMs are the most common innate immune cells
inhabiting tumors, and their presence contributes to tumorigenesis via the secretion of progrowth molecules, immunosuppressive factors, and extracellular matrix (ECM)-degrading
enzymes (Zhu et al. 2021). Additionally, prolonged inflammation in a tissue will leach reactive
oxygen species (ROS) which then cause genome instability and mutation, tying the two enabling
characteristics together and increasing tumorigenesis (Grivennikov et al. 2010).
Inflammation is a characteristic of most pre-cancerous growths, and the prolonged
inflammatory response tends to remain throughout the course of tumor progression (Hanahan
and Weinberg 2011). Currently, the only approved treatment for tumor-promoting inflammation
is the use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) ("Risk Factors: Chronic
Inflammation - National Cancer Institute" 2015). NSAIDs like Aspirin are generally safe with
temporary use, but their prolonged use can result in mild to severe stomach ulcers and
gastrointestinal bleeding (Huang et al. 2011). As tumor promoting inflammation is an enabling
characteristic that contributes to the carcinogenesis of other hallmarks, the authors of this paper
argue that a strong focus on this hallmark is necessary to the prevention of inflammatory diseases
including cancer.

A variety of Traditional Chinese Medicine (TCM) herbs have been demonstrated to
possess the ability to decrease the presence of TAMs, thereby regulating the prolonged
inflammatory response. Chinese skullcap, berberine, red peony root (Paeonia lactiflora), and
Monnier’s snowparsley (Cnidium monnieri) have TAM downregulation effects on tumors (He et
al. 2020). Curcumin in turmeric and capsaicin, the active component of chili peppers, have long
been appreciated for their general anti-inflammatory abilities (Kaefer and Milner 2011).

Hallmark 10: Genome Instability and
Mutation- an Enabling Characteristic

The final hallmark, genome instability and mutation, is the second enabling characteristic
of tumor progression. Spontaneous mutation rates are generally very low in the human body due
to DNA maintenance and repair mechanisms, however, induced mutation caused by
environmental factors such as ultraviolet light exposure and exposure to chemical carcinogens
can lead to mutations that promote the development of cancer (Hanahan and Weinberg 2011).
Increased sensitivity to mutagenic agents and malfunction in maintenance and repair
mechanisms are two primary deficiencies that increase the rate at which DNA mutates.
Chromosomal instability has been observed in approximately 60-80% of human cancers,

highlighting the importance that genome maintenance has in cancer prevention (Bakhoum and
Cantley 2018).
The most detrimental mutations are those which occur in housekeeping genes (genes that
are routinely “on'' for general cell upkeep and maintenance), genome repair genes, and tumor
suppressor genes. When a tumor suppressor gene, such as P53, becomes mutated, the cell loses
its ability to regulate the cell cycle, repair DNA, and trigger apoptosis. Additionally, mutations
that cause non-disjunction, or the failure to properly separate chromosomes during replication,
result in chromosomal breakage, translocations, or inversions. Non-disjunction can directly
influence cancer progression. Chromosomal instability at the end of chromosomes (telomeres)
specifically is known to be a key driver of carcinogenesis, while upregulation of telomerase
activity is a necessary characteristic of enabling replicative immortality. Telomere instability or
failure provides a starting point for oncogenesis, whereas constant telomere upkeep fuels the
continuation of oncogenesis. Clearly, proper telomere maintenance requires a delicate balance
between appropriate repair when damaged via mutation, while maintaining the normal
shortening of telomeres that comes with replication and promotes cell senescence. The overexpression of telomerase and subsequent unregulated lengthening of telomeres fuels
tumorigenesis (Hanahan and Weinberg 2011). Over time, preventative measures have become
increasingly important.
Thus, when considering treatment for genome instability and mutation, the seemingly
obvious path would be to upregulate DNA repair mechanisms. However, the uncontrolled
upregulation of DNA repair mechanisms can result in a tumor's ability to repair damage done by
reactive oxygen species (ROS) (Lagunas-Rangel and Bermúdez-Cruz 2020). As such, DNA
repair pathways are best supported before tumor formation, but can be harmful once a tumor has

begun growth. Currently, the focus is on drugs that target double strand break (DSB) repair.
DSB’s are some of the most carcinogenic events, thus it is critical to repair DSBs before they can
contribute to cancerous growth (Martin et al. 2009). Additionally, drugs inhibiting Poly ADPribose Polymerase (PARP), an enzyme that maintains chromosomal integrity, are being used to
make ovarian tumor cells more susceptible to mutation and make repair less likely (Morales et al.
2014). Side effects of the three FDA approved PARP inhibitors include anemia,
thrombocytopenia, neutropenia, nausea, vomiting, fatigue, and renal toxicity (LaFargue et al.
2019). DNA damage inducing drugs like cisplatin, as mentioned in evasion of growth
suppressors, are also used here to induce apoptosis by increasing genome mutations (Burgess et
al. 2020). DNA damage inducing drugs are risky, as the hallmark genome instability and
mutation is itself a driver of carcinogenesis.
The authors of this paper argue that a key preventative strategy for genome instability and
mutation is the support of P53 activity. Supporting proper P53 activity gives the body the
resources it needs to safely guard the genome and induce apoptosis when lethal mutations are
present. Since the strategy of upregulating DNA repair mechanisms can increase tumorigenesis,
it is advisable to support the body’s surveillance of mutations so that cell death can be induced as
necessary. Given the average human body has approximately 37 trillion cells, replacing a few
necrotic cells is safer than inadvertently giving cancerous cells the ability to repair their
mutations by upregulating DNA repair mechanisms. Therefore, the same herbs and plants that
promote P53 activity are pivotal in the prevention of genome instability and mutation.
Additionally, a few naturally occurring compounds have been discovered which have the ability
to protect against genome instability and mutation without promoting tumor repair. Resveratrol
naturally supports DNA resistance to ROS while down-regulating the repair pathways that tumor

cells use to fuel their growth and survival (Lagunas-Rangel and Bermúdez-Cruz 2020).
Curcumin and EGCG have both shown inhibition of certain kinds of DNA mutation repair
mechanisms in cancer cells while facilitating repair in normal cells. Curcumin and EGCG also
protect against UV damage (Lagunas-Rangel and Bermúdez-Cruz 2020). Preliminary data
suggest that resveratrol, curcumin, and EGCG show promise in supporting genome maintenance
in healthy cells while inhibiting cancer cell repair.

Conclusion
The authors of this study argue that while significant time and resources have been
committed to the treatment of cancer, relatively little work has been devoted to cancer
prevention. Given the complexity of this disease and the human body, a one-drug-for-onehallmark approach to treatment seems simplistic. Rather than waiting for tumorigenesis to begin
and only then addressing the disease, the authors argue that a lifestyle of prevention will result in
fewer cases of cancer and better treatment outcomes if a cancer diagnosis occurs. Nature has
provided many options for food-based medicine. Plants cannot simply outrun their predators, so
they have instead developed a complex chemical profile. Survival for plants requires complex
biochemical maneuverability. As a result, plants can provide the best source of preventative
medicines due to their incredibly diverse profile of polyphenols, flavonoids, alkaloids, and
secondary metabolites. The authors argue that the chemical complexity of plants is key to the
prevention and treatment of arguably the most complex disease we face, i.e. cancer.
Though over 30 compounds were noted in this study, a few were found to interact with
multiple hallmarks at once. Curcumin, EGCG, resveratrol, genistein, berberine, lutein, ginseng,
and astralagus were all shown to interact with at least two hallmarks. Special emphasis and study
should be given to these compounds for their anti-cancer potency, though all plants and herbs
noted in this study have been shown to have specific anti-cancer effects. Further studies on the in
vitro and in vivo activities of the identified compounds should be conducted, and methods by
which the identified compounds can be upregulated in their plants of origin should be
considered. This work does not present an exhaustive list of how to approach cancer prevention,
rather this work represents an effort to shift the focus from treatment to include prevention.

Much more work is needed to elucidate quantities, active compound interactions, and optimal
extraction conditions of the plants listed. As the search for plants with cancer preventing
properties continues, more options are expected to emerge.
This paper is not intended to provide an alternative for those battling cancer. The plants
and herbs listed should by no means replace chemotherapy. This work is intended to provide the
public with options to support their body’s natural tumor suppressive pathways using plants and
herbs to prevent cancerous growths from ever gaining a foothold in the body. The authors of this
paper recommend that the plants identified be taken with professional health advising, in
moderation, and generally in the plant’s whole, unaltered form. Supplements claiming to contain
the listed plants and herbs have the potential to be abused or taken in potentially dangerous
quantities. Whole plants and herbs are more difficult to be taken in harmful amounts. Anyone
with preexisting conditions or those currently on medications should consult a physician before
adding any plant or herb into their diet, as the authors recognize that the complexity of plants
also comes with the possibility of negative interactions with pharmaceuticals.
For any person desiring to protect their body from tumor growth or simply improve their
overall health, the plants and herbs identified provide a low risk, non-toxic, cost-effective, and
over-the-counter means of disease prevention.
Future work will focus on non-GMO modifications within the plants identified using an
adaptation of the CRISPR Cas-9 gene editing technology called CRISPR-on/off which functions
to epigenetically silence or activate a gene’s expression without altering the genome itself. The
result of this would be the production of non-GMO plants, in their native form that have
upregulated expression of their anti-cancer compound, making the plants more potent in their
tumor preventative qualities without altering the genetic code. The authors intend to

epigenetically modify medicinally relevant plants so that they will produce the medicinal
compounds at scale.
*All figures made with BioRender
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